-transparent.png){kind=logo}
A novel inhibitor of receptor-mediated calcium entry (RMCE) is described. SK&F 96365 (1-(beta-[3-(4-methoxy-phenyl)propoxy]-4-methoxyphenethyl)-1H- imidazole hydrochloride) is structurally distinct from the known 'calcium antagonists' and shows selectivity in blocking RMCE compared with receptor-mediated internal Ca2+ release. Human platelets, neutrophils and endothelial cells were loaded with the fluorescent Ca2(+)-indicator dyes quin2 or fura-2, in order to measure Ca2+ or Mn2+ entry through RMCE as well as Ca2+ release from internal stores. The IC50 (concn. producing 50% inhibition) for inhibition of RMCE by SK&F 96365 in platelets stimulated with ADP or thrombin was 8.5 microM or 11.7 microM respectively; these concentrations of SK&F 96365 did not affect internal Ca2+ release. Similar effects of SK&F 96365 were observed in suspensions of neutrophils and in single endothelial cells. SK&F 96365 also inhibited agonist-stimulated Mn2+ entry in platelets and neutrophils. The effects of SK&F 96365 were independent of cell type and of agonist, as would be expected for a compound that modulates post-receptor events. Voltage-gated Ca2+ entry in fura-2-loaded GH3 (pituitary) cells and rabbit ear-artery smooth-muscle cells held under voltage-clamp was also inhibited by SK&F 96365; however, the ATP-gated Ca2(+)-permeable channel of rabbit ear-artery smooth-muscle cells was unaffected by SK&F 96365. Thus SK&F 96365 (unlike the 'organic Ca2+ antagonists') shows no selectivity between voltage-gated Ca2+ entry and RMCE, although the lack of effect on ATP-gated channels indicates that it discriminates between different types of RMCE. The effects of SK&F 96365 on functional responses of cells thought to be dependent on Ca2+ entry via RMCE were also studied. Under conditions where platelet aggregation is dependent on stimulated Ca2+ entry via RMCE, the response was blocked by SK&F 96365 with an IC50 of 15.9 microM, which is similar to the IC50 of 8-12 microM observed for inhibition of RMCE. Adhesion and chemotaxis of neutrophils were also inhibited by SK&F 96365. SK&F 96365 is a useful tool to distinguish RMCE from internal Ca2+ release, and to probe the role of RMCE in mediating functional responses of cells. However, SK&F 96365 is not as potent (IC50 around 10 microM) or selective (also inhibits voltage-gated Ca2+ entry) as would be desirable, so caution must be exercised when using this compound.
J E Merritt, and
W P Armstrong, and
C D Benham, and
T J Hallam, and
R Jacob, and
A Jaxa-Chamiec, and
B K Leigh, and
S A McCarthy, and
K E Moores, and
T J Rink
March 1992,
Molecular pharmacology,
J E Merritt, and
W P Armstrong, and
C D Benham, and
T J Hallam, and
R Jacob, and
A Jaxa-Chamiec, and
B K Leigh, and
S A McCarthy, and
K E Moores, and
T J Rink
June 1991,
Biochemical and biophysical research communications,
J E Merritt, and
W P Armstrong, and
C D Benham, and
T J Hallam, and
R Jacob, and
A Jaxa-Chamiec, and
B K Leigh, and
S A McCarthy, and
K E Moores, and
T J Rink
February 1998,
The Journal of pharmacology and experimental therapeutics,
J E Merritt, and
W P Armstrong, and
C D Benham, and
T J Hallam, and
R Jacob, and
A Jaxa-Chamiec, and
B K Leigh, and
S A McCarthy, and
K E Moores, and
T J Rink
February 1995,
British journal of pharmacology,
J E Merritt, and
W P Armstrong, and
C D Benham, and
T J Hallam, and
R Jacob, and
A Jaxa-Chamiec, and
B K Leigh, and
S A McCarthy, and
K E Moores, and
T J Rink
March 2000,
Japanese journal of pharmacology,
J E Merritt, and
W P Armstrong, and
C D Benham, and
T J Hallam, and
R Jacob, and
A Jaxa-Chamiec, and
B K Leigh, and
S A McCarthy, and
K E Moores, and
T J Rink
August 1994,
Neuroscience letters,
J E Merritt, and
W P Armstrong, and
C D Benham, and
T J Hallam, and
R Jacob, and
A Jaxa-Chamiec, and
B K Leigh, and
S A McCarthy, and
K E Moores, and
T J Rink
November 1993,
European journal of pharmacology,
J E Merritt, and
W P Armstrong, and
C D Benham, and
T J Hallam, and
R Jacob, and
A Jaxa-Chamiec, and
B K Leigh, and
S A McCarthy, and
K E Moores, and
T J Rink
October 1992,
Experimental cell research,
J E Merritt, and
W P Armstrong, and
C D Benham, and
T J Hallam, and
R Jacob, and
A Jaxa-Chamiec, and
B K Leigh, and
S A McCarthy, and
K E Moores, and
T J Rink
June 1994,
Journal of biomedical science,
J E Merritt, and
W P Armstrong, and
C D Benham, and
T J Hallam, and
R Jacob, and
A Jaxa-Chamiec, and
B K Leigh, and
S A McCarthy, and
K E Moores, and
T J Rink
March 1996,
Biochemical pharmacology,
